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Purpose: To identify the prognostic factors related to tumor recurrence and progression in Korean patients with non-muscle-in-
vasive bladder cancer (NMIBC).
Materials and Methods: Data were collected and analyzed for 2412 NMIBC patients from 15 centers who were initially diagnosed 
after transurethral resection of bladder tumor (TURBT) from January 2006 to December 2010. Using univariable and multivariable 
Cox proportional hazards models, the prognostic value of each variable was evaluated for the time to first recurrence and progression.
Results: With a median follow-up duration of 37 months, 866 patients (35.9%) experienced recurrence, and 137 (5.7%) experi-
enced progression. Patients with recurrence had a median time to the first recurrence of 10 months. Multivariable analysis con-
ducted in all patients revealed that preoperative positive urine cytology (PUC) was independently associated with worse recur-
rence-free survival [RFS; hazard ratio (HR) 1.56; p<0.001], and progression-free survival (PFS; HR 1.56; p=0.037). In particular, on 
multivariable analysis conducted for the high-risk group (T1 tumor/high-grade Ta tumor/carcinoma in situ), preoperative PUC 
was an independent predictor of worse RFS (HR 1.73; p<0.001) and PFS (HR 1.96; p=0.006). On multivariable analysis in patients 
with T1 high-grade (T1HG) cancer (n=684), better RFS (HR 0.75; p=0.033) and PFS (HR 0.33; p<0.001) were observed in associa-
tion with the administration of intravesical Bacillus Calmette-Guérin (BCG) induction therapy.
Conclusion: A preoperative PUC result may adversely affect RFS and PFS, particularly in high-risk NMIBC patients. Of particular 
note, intravesical BCG induction therapy should be administered as an adjunct to TURBT in order to improve RFS and PFS in pa-
tients with T1HG cancer.
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INTRODUCTION
Bladder cancer is the second most common malignancy of the 
genitourinary tract and shows a male predominance.1,2 In the 
United States, bladder cancer was ranked fourth, considering 
the incidence among all newly diagnosed cancers in men in 
2014.1 It is also estimated that in Korea, a total of 4173 cases 
were newly diagnosed in 2014, giving bladder cancer a rank of 
seventh, considering the incidence in men.2 Urothelial carcino-
ma of the bladder (UCB) is the most common histologic type, 
accounting for 80–90% of all bladder cancer. Approximately 
75% of patients with UCB are initially diagnosed with non-
muscle-invasive bladder cancer (NMIBC), which is confined 
to either the mucosa [pTa, carcinoma in situ (CIS)] or the sub-
mucosa (pT1).3 Transurethral resection of bladder tumor (TU-
RBT) is primarily used for confirmative diagnostic and thera-
peutic purposes in NMIBC. However, a substantial number of 
patients (50–70%) experience disease recurrence within 5 
years after TURBT, and 10–20% of tumors that have recurred 
progress to higher-stage (muscle invasion) or higher-grade 
disease.3,4 Therefore, the prevention of disease recurrence and 
progression is an important issue in the management of NM-
IBC, resulting in the need for adjuvant therapy in nearly all 
NMIBC patients. 
The recognition of prognostic factors associated with the re-
currence and progression of NMIBC is crucial for patient coun-
seling and clinical decision making related to adjuvant therapy, 
such as intravesical chemotherapy (IVC) and Bacillus Calmet-
te-Guérin (BCG) immunotherapy. Both pathologic tumor stage 
and grade are essentially determinant prognosticators for NMI-
BC. In particular, T1 high-grade (T1HG) UCB has a higher risk 
of disease recurrence and progression than other forms of 
NMIBC.5,6 In addition, many studies have investigated the po-
tential prognostic value of multiple factors, including sex, age, 
smoking, preoperative urine cytology result, tumor size, tumor 
morphology, tumor multiplicity, CIS, included muscle layer, 
lymphovascular invasion (LVI), restaging transurethral resec-
tion (TUR), and intravesical BCG therapy, in association with 
the recurrence and progression of NMIBC.7-13 The prognostic 
value of several of these factors has been established, while 
such value remains controversial for others. 
In this study, we aimed to confirm the prognostic factors sig-
nificantly associated with recurrence and progression after TUR-
BT in a large multicenter cohort of Korean patients with NMIBC.
MATERIALS AND METHODS
Study population
Before the initiation of this multicenter and retrospective study, 
Institutional Review Board approval was obtained for the use 
of individual patient data from each center. A total of 3462 pa-
tients who underwent initial TURBT for bladder cancer at their 
respective institutions between January 2006 and December 
2010 were initially recruited from 15 centers. Inclusion criteria 
were as follows: 1) histologically confirmed urothelial carci-
noma; 2) NMIBC including Tis or Ta or T1 tumors; and 3) fol-
low-up for at least 1 year after TURBT. Exclusion criteria in-
cluded patients with a previous or concomitant history of upper 
tract urothelial carcinoma, patients with malignancy of anoth-
er site of origin, patients with non-urothelial carcinoma, and 
patients who had a history of chemotherapy, immunotherapy, 
or immunosuppressive agent administration within 6 months. 
Ultimately, a total of 2412 patients consisting of between 21 and 
431 patients per center were eligible for this study.
Acquisition of data and definition of variables
Potential clinicopathological data were extracted from our 
multi-institutional database. Clinical (preoperative) variables 
included age (<65 years vs. ≥65 years), sex, urine cytology re-
sult, tumor morphology (papillary vs. non-papillary), tumor 
multiplicity (single vs. multiple), and tumor size (<3 cm vs. ≥3 
cm). Preoperative urine cytology was examined using voided 
urine at the first visit prior to initial TURBT. Urine cytology re-
sult was described as one of the following three categories: ne-
gative, atypical cells, or positive for malignant cells. Positive 
urine cytology (PUC) was defined only as positive for malignant 
cells in a voided urine sample. The tumor stage (Ta vs. T1/Tis) 
and grade (low vs. high) of all initial TURBT specimens were 
assessed by genitourinary pathologists with expertise and de-
termined according to the 2010 Tumor-Node-Metastasis classi-
fication of the American Joint Committee on Cancer (7th edi-
tion) and the 2004 World Health Organization system, res-
pectively. The presence of concomitant CIS and muscle layer 
in the specimen were also identified from pathologic reports. 
Restaging TURBT was not routinely performed in our database 
and was determined at the discretion of the surgeon. Variables 
related to postoperative adjuvant therapy, such as immediate 
(within 24 h after TURBT) IVC, additional IVC and chemother-
apeutic agents (e.g., mitomycin, epirubicin, and adriamycin), 
and intravesical BCG immunotherapy including induction 
and maintenance, were recorded. BCG for induction was usu-
ally initiated within 2–6 weeks following TURBT and repeated 
once weekly for 6 weeks (6 cycles). Any instillations beyond 6 
cycles were viewed as maintenance BCG. The end-points of 
interest were time to disease recurrence and progression. Re-
currence was defined as the first tumor relapse in the bladder 
or prostatic urethra irrespective of tumor stage. Progression was 
defined as the presence of muscle invasive disease (≥T2) or 
metastatic disease at the time of tumor recurrence.
Risk group stratification 
All patients were stratified into each risk group according to 
several factors, which included tumor stage (Ta vs. T1/Tis), tu-
mor grade (low vs. high), tumor multiplicity (single vs. multiple) 
and tumor size (<3 cm vs. ≥3 cm).3 Eventually, NMIBC patients 
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were categorized into low-, intermediate-, and high-risk groups 
(Supplementary Table 1, only online). The high-risk group con-
tained patients with any findings of following: T1 tumors, high-
grade Ta tumors, and CIS.
 
Follow-up protocol
Patients were usually followed up at least every 3–4 months for 
the first 2 years, semiannually for the next 3 years, and annually 
thereafter with urine cytology, cystoscopy, and biopsy of suspi-
cious lesions. Radiographic assessment of the upper urinary 
tract was generally carried out at the initial diagnosis and there-
after only in cases of disease recurrence or suspicion, such as 
PUC. Recurrence-free survival (RFS) was defined as the interval 
between the day of the TURBT and the time of the first tumor 
recurrence. Progression-free survival (PFS) was defined as the 
interval from the date of the TURBT to the date of disease pro-
gression.
 
Statistical analyses
For the entire study cohort, continuous and categorical vari-
ables are respectively expressed as median and interquartile 
range (IQR) and absolute numbers and relative percentages (%) 
in accordance with descriptive and frequency analyses. The 
Kaplan-Meier method with the log-rank test was used to esti-
mate and compare the RFS and PFS according to each poten-
tial prognostic factor. The significant factors related to recur-
rence and progression identified using univariable Cox pro-
portional hazard regression models were incorporated into a 
step-down multivariable Cox regression analysis to confirm 
the definitive prognostic factors. All statistical analyses were 
conducted using SPSS software version 21.0 (SPSS Inc., Chica-
go, IL, USA), and two-sided p values of <0.05 were considered 
to be statistically significant.
RESULTS
Characteristics of the study cohort
Baseline characteristics of all patients (n=2412) are summa-
rized in Table 1. Preoperative variables showed that the medi-
an age of patients was 64.5 years, the male-to-female ratio was 
approximately 5:1, 39.3% were smokers at the time of diagno-
sis, 24.5% presented PUC results, 85.4% had papillary tumor 
morphology, 42.7% had multiple tumors, and 58.5% had tu-
mors of less than 3 cm in size. On pathologic review, 56.7% of 
specimens showed Ta tumors, 47.4% demonstrated high-grade 
tumors, 8.3% had a primary or concomitant CIS, and definite 
muscle layer was observed in 38.5%, showing a significant dif-
ference between Ta and T1 disease (31% vs. 50.3%; p<0.001). 
As a result of risk stratification, a total of 550 (22.8%), 429 (17.8%), 
and 1433 patients (59.4%) were respectively incorporated into 
the low-, intermediate-, and high-risk groups. Among the entire 
group of patients, 684 showed T1HG disease. After TURBT, in-
travesical instillation within 24 h was performed in 453 (18.8%) 
patients, while additional IVC and induction BCG therapy were 
administered in 417 (17.3%) and 1299 (53.9%) patients, re-
spectively. BCG maintenance was carried out in 648 patients 
(26.8%).
Clinical outcomes in the entire study cohort 
(n=2412)
The median follow-up duration for all patients was 37 months, 
with a minimum follow-up duration of 12 months and a maxi-
mum of 81 months. A total of 866 patients (35.9%) experienced 
a first recurrence, with a median time to recurrence of 10 months 
(IQR 5–19 months). Disease progression was observed in 137 
patients (5.7%), divided into muscle invasion (79 patients) and 
distant metastasis (58 patients), with a mean follow-up dura-
tion of 37 months (IQR 25–52 months) (Table 1). 
Applying the Kaplan-Meier method with the log-rank test, 
patients with preoperative PUC showed a worse 5-year RFS rate 
than those with a negative result (44.8% vs. 61.2%; p<0.001) (Fig. 
1A). There was also a significant difference in the 5-year PFS 
rate between patients with positive and negative urine cytology 
results (84.3% vs. 91.4%; p<0.001) (Fig. 1B).
The results of regression analyses using univariable and mul-
tivariable Cox proportional hazards models for RFS and PFS 
are listed in Tables 2 and 3. Multivariable analyses revealed that 
a PUC result was an independent predictor of worse RFS [haz-
ard ratio (HR) 1.56; 95% confidence interval (CI) 1.29–1.89; 
p<0.001] and PFS (HR 1.56; 95% CI 1.03–2.38; p<0.037). Ad-
vanced age (≥65 years) was also identified as an independent 
predictor of worse RFS (HR 1.34; 95% CI 1.13–1.59; p=0.001) 
and PFS (HR 2.13; 95% CI 1.44–3.16; p<0.001). A high tumor 
grade was significantly related to poor PFS (HR 2.13; 95% CI 
1.39–3.25; p<0.001). 
Clinical outcomes according to each risk group in the 
entire cohort
When stratifying the patients into each risk group according 
to the definition (Supplementary Table 1, only online), there 
were significant differences among risk groups in terms of age, 
preoperative urine cytology results, tumor morphology, includ-
ed muscle layer, administration of adjuvant intravesical therapy 
(immediate IVC, additional IVC, induction BCG, and mainte-
nance BCG) (Supplementary Table 2, only online). The results 
of the survival analysis using the Kaplan-Meier method with 
the log-rank test indicated that the RFS and PFS rates were well 
discriminated between each risk group (Fig. 2). Interestingly, 
these survival curves for RFS and PFS showed similar trends to 
those in cases of preoperative urine cytology results in the en-
tire study cohort (Fig. 1). 
On univariable analysis of the intermediate-risk group, there 
were no significant prognostic factors related to recurrence or 
progression. For the low-risk group, multivariable analysis sh-
owed that induction BCG instillation (HR 1.76; 95% CI 1.25–
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2.48; p=0.001) was significantly associated with worse RFS (Sup-
plementary Table 3, only online), while there were no relevant 
factors with a risk of progression on univariable analysis, ex-
cept for advanced age (HR 5.81; 95% CI 1.55–20.02; p=0.008) 
(Supplementary Table 4, only online). Notably, only for the 
high-risk group, multivariable analyses revealed that preoper-
ative PUC was confirmed as an independent predictive factor 
of worse RFS (HR 1.73; 95% CI 1.38–2.18; p<0.001) and PFS (HR 
1.96; 95% CI 1.22–3.16; p=0.006) (Table 4).
Clinical outcomes in patients with T1HG cancer 
(n=684)
The first disease recurrence was found in 258 (37.7%) patients, 
with a median time to recurrence of 8 months (IQR 4.0–17.5 
months). Among these patients, disease progression was not-
ed in 71 (10.4%), with a median follow-up duration of 36 months 
(IQR 24–50 months). Progression to muscle invasion and dis-
tant metastasis was documented in 39 (5.7%) and 32 patients 
(4.8%), respectively. 
On Kaplan-Meier analysis with the log-rank test, patients 
who received induction BCG therapy after TURBT showed bet-
ter 5-year RFS (57.3% vs. 37.4%; p=0.019) (Fig. 3A) and PFS 
(85.8% vs. 59.0%; p<0.001) (Fig. 3B) than those who received 
no induction BCG. After conducting the multivariable Cox re-
gression analyses with adjustment for other significant vari-
ables identified on univariable analyses, induction BCG ther-
apy remained an independent predictor of improved RFS (HR 
0.75; 95% CI 0.57–0.98; p=0.033) and PFS (HR 0.33; 95% CI 
0.20–0.53; p<0.001) (Table 5). 
Table 1. Baseline Characteristics of the Entire Study Cohort (n=2412)
Variables Total (n=2412)
Clinical parameters
Age, yr, median (IQR) 64.5 (57.3–72.7)
<65, n (%) 1099 (45.6)
≥65, n (%) 1313 (54.4)
Gender, n (%)
Male 1847 (76.6)
Female 368 (15.3)
Missing/unknown 197 (8.2)
Preoperative urine cytology, n (%)
Negative 1132 (46.9)
Atypical cells 448 (18.6)
Positive for malignant cells 593 (24.5)
Missing/unknown 239 (10)
Tumor morphology, n (%)
Papillary 2060 (85.4)
Non-papillary (sessile/flat/mixed) 346 (14.3)
Missing/unknown 6 (0.3)
Tumor multiplicity, n (%)
Single 1357 (56.3)
Multiple (≥2) 1031 (42.7)
Missing/unknown 24 (1.0)
Tumor size, n (%)
<3 cm 1411 (58.5)
≥3 cm 664 (27.5)
Missing/unknown 337 (14.0)
Pathological parameters
Tumor stage, n (%)
pTa 1368 (56.7)
pT1/Tis 1042 (43.2)
Missing/unknown 2 (0.1)
Tumor grade, n (%)
Low-grade 1140 (47.3)
High-grade 1143 (47.4)
Missing/unknown 129 (5.3)
Carcinoma in situ, n (%)
Absent 2131 (88.3)
Present (primary or concomitant) 200 (8.3)
Missing/unknown 81 (3.4)
Muscle layer included, n (%)
Absent 1480 (61.4)
Present 928 (38.5)
Missing/unknown 4 (0.2)
Postoperative parameters
Immediate intravesical instillation, n (%)
No 1951 (80.9)
Yes 453 (18.8)
Missing/unknown 8 (0.3)
Additional intravesical chemotherapy, n (%)
No 1983 (82.2)
Yes 417 (17.3)
Missing/unknown 12 (0.5)
Table 1. Baseline Characteristics of the Entire Study Cohort (n=2412) 
(Continued)
Variables Total (n=2412)
BCG induction, n (%)
No 1113 (46.1)
Yes 1299 (53.9)
BCG maintenance, n (%)
No 1573 (65.2)
Yes 648 (26.8)
Missing/unknown 191 (7.9)
Overall follow-up duration (months), median (IQR) 37 (25–52)
Median first time to recurrence (months) 10 (5–19)
Recurrence, n (%)
No 1543 (64.0)
Yes 866 (35.9)
Missing/unknown 3 (0.1)
Progression, n (%)
No 2263 (93.8)
Yes 137 (5.7)
Muscle invasion 79
Distant metastasis 58
Missing/unknown 12 (0.5)
IQR, interquartile range; BCG, Bacillus Calmette-Guérin.
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DISCUSSION
Although NMIBC may be treated by TURBT alone, high recur-
rence (50–70%) and progression (10–20%) rates can be prob-
lematic in the management of most NMIBC cases.3,4 Therefore, 
it is necessary to consider adjuvant therapy in most patients to 
prevent disease recurrence and progression. To make an ap-
propriate decision regarding adjuvant therapy, it is also impor-
tant to recognize the factors predicting prognosis after TURBT. 
To predict the risks of both recurrence and progression in 
individual patients with Ta and T1 tumors, a scoring system 
and risk tables, which were based on the six most significant 
clinical and pathological factors, including tumor multiplicity, 
tumor size, prior recurrence rate, T category, presence of con-
Fig. 1. Kaplan-Meier plots for recurrence-free survival (A) and progression-free survival (B) stratified by urine cytology result for the entire study cohort.
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Table 2. Univariable and Multivariable Cox Regression Analyses Predicting Recurrence-Free Survival in the Entire Study Cohort (n=2412)
Variables
Univariable analysis Multivariable analysis
Unadjusted HR (95% CI) p value Adjusted HR (95% CI) p value
Clinical parameters
Age, yrs (≥65 vs. <65) 1.37 (1.19–1.57) <0.001 1.34 (1.13–1.59) 0.001
Gender (female vs. male) 1.02 (0.85–1.22) 0.852
Preoperative urine cytology (ref. negative)
Atypical cells 1.20 (1.00–1.45) 0.049 1.10 (0.88–1.38) 0.411
Positive for malignant cells 1.62 (1.38–1.90) <0.001 1.56 (1.29–1.89) <0.001
Tumor morphology (non-papillary vs. papillary) 1.20 (0.99–1.43) 0.053
Tumor multiplicity (multiple vs. single) 1.29 (1.13–1.48) <0.001 1.07 (0.90–1.28) 0.445
Tumor size, cm (≥3 vs. <3) 1.28 (1.10–1.49) 0.001 1.07 (0.89–1.28) 0.479
Pathological parameters
Tumor stage (pT1/Tis vs. ≤pTa) 1.11 (0.97–1.27) 0.114
Tumor grade (high vs. low) 1.54 (1.34–1.77) <0.001 1.13 (0.93–1.37) 0.206
Carcinoma in situ (present vs. absent) 1.26 (1.01–1.58) 0.039 1.09 (0.81–1.46) 0.556
Muscle layer included (present vs. absent) 0.95 (0.83–1.09) 0.508
Postoperative parameters
Immediate intravesical chemotherapy (yes vs. no) 0.89 (0.75–1.06) 0.203
Induction BCG (yes vs. no) 1.29 (1.13–1.48) <0.001 0.99 (0.81–1.21) 0.914
Maintenance BCG (yes vs. no) 1.31 (1.13–1.52) <0.001 1.20 (0.99–1.46) 0.061
HR, hazard ratio; CI, confidence interval; BCG, Bacillus Calmette-Guérin.
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current CIS, and tumor grade, were developed by the Europe-
an Organization for Research and Treatment of Cancer (EO-
RTC) and validated by several investigators.14-16 The Spanish 
Urological Club for Oncological Treatment (CUETO) scoring 
model was also developed to stratify the risk of recurrence and 
progression in NMIBC treated with BCG.17 Incorporated vari-
ables for the model were sex, age, tumor grade, tumor status 
(primary, recurrent), multiplicity, and associated Tis for recur-
rence, and age, grade, tumor status, T category, multiplicity, 
and associated Tis for progression. The prognostic values of 
each variable involved in the EORTC risk tables or CUETO sc-
oring model have also been described in selected patient popu-
lations. One multicenter study has reported that advanced age 
(70 years or older), large tumor size (3 cm or greater), and con-
Table 3. Univariable and Multivariable Cox Regression Analyses for Predicting Progression-Free Survival in the Entire Study Cohort (n=2412)
Variables
Univariable analysis Multivariable analysis
Unadjusted HR (95% CI) p value Adjusted HR (95% CI) p value
Clinical parameters
Age, yrs (≥65 vs. <65) 2.02 (1.41–2.88) <0.001 2.13 (1.44–3.16) <0.001
Gender (female vs. male) 1.35 (0.86–2.12) 0.185
Preoperative urine cytology (ref. negative)
Atypical cells 1.23 (0.75–2.01) 0.420 0.89 (0.53–1.51) 0.665
Positive for malignant cells 2.32 (1.57–3.45) <0.001 1.56 (1.03–2.38) 0.037
Tumor morphology (non-papillary vs. papillary) 1.47 (0.96–2.25) 0.078
Tumor multiplicity (multiple vs. single) 1.35 (0.97–1.90) 0.078
Tumor size, cm (≥3 vs. <3) 1.11 (0.75–1.63) 0.611
Pathological parameters
Tumor stage (pT1/Tis vs. ≤pTa) 2.37 (1.67–3.37) <0.001 1.39 (0.93–2.09) 0.111
Tumor grade (high vs. low) 2.67 (1.82–3.93) <0.001 2.13 (1.39–3.25) <0.001
Carcinoma in situ (present vs. absent) 1.33 (0.77–2.27) 0.303
Muscle layer included (present vs. absent) 1.03 (0.73–1.46) 0.851
Postoperative parameters
Immediate intravesical chemotherapy (yes vs. no) 1.10 (0.71–1.70) 0.674
Induction BCG (yes vs. no) 1.16 (0.83–1.63) 0.388
Maintenance BCG (yes vs. no) 0.74 (0.49–1.12) 0.151
HR, hazard ratio; CI, confidence interval; BCG, Bacillus Calmette-Guérin.
Fig. 2. Kaplan-Meier plots for recurrence-free survival (A) and progression-free survival (B) according to risk stratification.
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comitant CIS showed a close association with a high risk of 
progression in patients with T1G3 tumors who received BCG.13 
In high-risk NMIBC (Ta, T1) patients treated with BCG, tumor 
size (<3 cm, ≥3 cm) and T stage (Ta, T1) correlated with recur-
rence and progression, respectively.12 Female sex was related 
to worse RFS, PFS, and cancer-specific survival (CSS) in pa-
tients with T1HG disease.8,9 Other prognostic factors were also 
evaluated in several studies. Smoking status and immediate 
Table 4. Multivariable Cox Regression Analyses for Predicting Recurrence-Free Survival (RFS) and Progression-Free Survival (RFS) in High-Risk Pa-
tients (n=1433)
Variables
RFS PFS
Adjusted HR (95% CI) p value Adjusted HR (95% CI) p value
Clinical parameters
Age, yrs (≥65 vs. <65) 1.20 (0.98–1.47) 0.074 1.80 (1.16–2.79) 0.008
Preoperative urine cytology (ref. negative)
Atypical cells 1.23 (0.93–1.62) 0.149 1.13 (0.62–2.07) 0.682
Positive for malignant cells 1.73 (1.38–2.18) <0.001 1.96 (1.22–3.16) 0.006
Tumor size, cm (≥3 vs. <3) 1.15 (0.94–1.41) 0.181
Postoperative parameters
Induction BCG (yes vs. no) 0.78 (0.48–1.25) 0.296
Maintenance BCG (yes vs. no) 1.06 (0.85–1.32) 0.632 0.76 (0.46–1.23) 0.265
HR, hazard ratio; CI, confidence interval; BCG, Bacillus Calmette-Guérin.
Fig. 3. Kaplan-Meier plots for recurrence-free survival (A) and progression-free survival (B) stratified by induction intravesical BCG for patients with T1 
high-grade urothelial carcinoma. BCG, Bacillus Calmette-Guérin.
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Table 5. Multivariable Cox Regression Analyses for Predicting Recurrence-Free Survival (RFS) and Progression-Free Survival (PFS) in Patients with 
T1 High-Grade Urothelial Carcinoma (n=684)
Variables
RFS PFS
Adjusted HR (95% CI) p value Adjusted HR (95% CI) p value
Clinical parameters
Age, yrs (≥65 vs. <65) 1.39 (1.07–1.79) 0.012 1.60 (0.97–2.62) 0.065
Postoperative parameters
Induction BCG (yes vs. no) 0.75 (0.57–0.98) 0.033 0.33 (0.20–0.53) <0.001
Maintenance BCG (yes vs. no) 0.75 (0.39–1.44) 0.389
HR, hazard ratio; CI, confidence interval; BCG, Bacillus Calmette-Guérin.
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intravesical instillation were reported as significant predictors 
of recurrence in all NMIBC cases.7,18 In T1HG tumors, papil-
lary tumor architecture (vs. sessile), no LVI, non-trigonal tumor 
location, intravesical BCG therapy, and presence of muscle 
layer in TURBT specimen were suggested as factors associat-
ed with improved PFS.5,11
In the present study, the prognostic factors mentioned above 
showed various clinical implications in association with prog-
nosis after TURBT. Similarly to the existing studies,14-17 ad-
vanced age and high tumor grade were identified as significant 
factors related to worse RFS and/or PFS. In contrast, the defini-
tive prognostic impact of tumor multiplicity, tumor size, and 
CIS on recurrence was not confirmed on multivariable analy-
sis. Unlike in previous studies,7-9,11,18 sex, the presence of muscle 
layer, and immediate intravesical instillation had no effect on 
the risk of recurrence and progression in all NMIBC patients. 
Although it was not described in detail in the present study, 
the administration of additional IVC showed no consistent ef-
fect in terms of the prevention of recurrence and progression. 
While IVC showed a worse result for recurrence in all NMIBC 
and T1HG patients, it demonstrated a better outcome for pro-
gression in all NMIBC patients. Moreover, in all risk groups, 
the administration of additional IVC was not associated with 
favorable RFS or PFS. These findings are different from the re-
sults of a previous meta-analysis, which demonstrated a signi-
ficant reduction of recurrence and no effect on tumor progres-
sion with regard to additional IVC.19 Owing to these conflicting 
findings in the present study, we excluded the additional IVC 
as a covariate when performing the survival analysis. The po-
tential causes for these conflicting findings are as followings. 
First of all, due to the multi-institutional and retrospective na-
ture, there was no unified central pathologic review. Eventually, 
the interpretation of pathological variables, including tumor 
stage, grade, and urine cytology results, may be different de-
pending on each center, such that the indications for IVC were 
differently applied among institutions. Additionally, as there is 
currently no established standard concerning the duration and 
frequency of IVC use in NMIBC,20 the type of agent, duration, 
and interval for IVC may be diversely adopted at the discretion 
of physicians at each hospital, allowing the generation of these 
conflicting findings. 
Above all, the notable finding of the current study was the 
confirmation of the prognostic value of preoperative urine cy-
tology results in association with recurrence and progression 
after TURBT. Along with cystoscopy, urine cytology is currently 
the standard method for the diagnosis and surveillance of blad-
der cancer.21,22 PUC is reported with high frequency in cases of 
high-grade tumor or CIS, which shows reduced intercellular 
adhesion and produces a greater number of cells shed into 
the urine. In the present study, PUC was a significant factor re-
lated to a high risk of recurrence and progression among all 
NMIBC patients. Particularly, on multivariable analysis con-
ducted only in high-risk patients including high-grade and CIS 
disease, preoperative PUC was an independent predictor of 
both RFS and PFS. Moreover, survival curves for RFS and PFS 
showed similar tendencies between preoperative urine cytol-
ogy results and risk stratification. Therefore, PUC may play a 
role as a surrogate marker for predicting disease recurrence 
and progression after TURBT. This adverse association be-
tween PUC and the prognosis of urothelial carcinoma has been 
found in several previous studies.23-25 
T1HG UCBs are at a higher risk of disease recurrence and 
progression than other NMIBCs. Therefore, adjuvant intraves-
ical BCG immunotherapy as an adjunct to TURBT is currently 
mandatory in the management of T1HG tumors to improve 
prognosis.3,4 In our study, approximately 75% and 35% of pa-
tients with T1HG tumors received induction and maintenance 
BCG therapy, respectively. T1HG patients who received induc-
tion BCG therapy showed improved RFS and PFS, and main-
tenance BCG was also significantly associated with better PFS 
on univariable analysis. The results of multivariable analysis in 
T1HG patients showed that improved RFS and PFS was ob-
served only in association with induction BCG therapy. These 
findings are in agreement with those of a previous study, which 
suggests that adjuvant BCG therapy was significantly associ-
ated with prolonged RFS and worsening-free survival (PFS and 
CSS).5
Our study had several limitations. Owing to its multicenter 
and retrospective design, the accuracy in reporting prognostic 
factors such as sex, urine cytology results, tumor size, tumor 
grade, and maintenance BCG suffered from missing data. We 
also could not standardize the quality of TURBT or indications 
for adjuvant intravesical therapy and restaging TURBT. In par-
ticular, due to the various treatment patterns across institutions, 
it was difficult to assess which procedure, including restaging 
TURBT or adjuvant intravesical therapy, significantly reduced 
residual tumors and subsequently improved the management 
of NMIBC patients. In addition, we could not adjust for the 
number and experience of surgeons and pathologists at each 
center; therefore, there was no central pathology review. How-
ever, these factors can also be interpreted as additional strengths 
of this study, as they reflect real clinical practice and thus ex-
tend the generalizability of the results. Finally, we did not take 
into account comorbidities of patients, treatment-related com-
plications, and several pathologic variables, such as LVI and 
variant histology of UCB, which might have affected the deci-
sion-making regarding further therapy, resulting in a possible 
selection bias. Consequently, the results drawn from this study 
should be further verified through well-designed prospective 
and randomized clinical trials. 
In conclusion, preoperative PUC may adversely affect the 
prognosis after TURBT, particularly in high-risk NMIBC pa-
tients. In particular, patients with T1HG disease treated with at 
least an induction course of intravesical BCG after TURBT sh-
owed better RFS and PFS outcomes. Therefore, BCG immuno-
therapy should be considered in NMIBC patients for the pre-
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vention of disease recurrence and progression. Further pro-
spective research will be required to verify these findings.
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